Wall Street Zen Upgrades Theravance Biopharma (NASDAQ:TBPH) to “Strong-Buy”

Theravance Biopharma (NASDAQ:TBPH) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Sunday.

Other research analysts also recently issued research reports about the company. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. B. Riley began coverage on Theravance Biopharma in a research note on Friday, September 12th. They set a “buy” rating and a $28.00 target price for the company. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. BTIG Research boosted their price objective on shares of Theravance Biopharma from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, November 26th. Finally, Oppenheimer initiated coverage on Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $27.80.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $17.77 on Friday. The stock’s 50-day simple moving average is $16.41 and its 200-day simple moving average is $13.72. The firm has a market capitalization of $900.41 million, a PE ratio of 31.18 and a beta of 0.14. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $20.33.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. On average, sell-side analysts forecast that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares in the company, valued at $5,206,781.25. This trade represents a 10.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Assenagon Asset Management S.A. purchased a new position in shares of Theravance Biopharma during the second quarter valued at approximately $264,000. Cubist Systematic Strategies LLC bought a new position in Theravance Biopharma during the 1st quarter valued at $419,000. Acadian Asset Management LLC boosted its holdings in Theravance Biopharma by 121,993.7% during the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company’s stock worth $1,554,000 after acquiring an additional 174,451 shares during the last quarter. PDT Partners LLC grew its stake in shares of Theravance Biopharma by 135.1% in the 1st quarter. PDT Partners LLC now owns 88,577 shares of the biopharmaceutical company’s stock worth $791,000 after acquiring an additional 50,901 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Theravance Biopharma by 3.5% in the first quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company’s stock valued at $18,579,000 after purchasing an additional 69,919 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.